This article is more than 5 years old. Information may no longer be current.

Namodenoson compassionate use program for HCC launches

Can-Fite BioPharma announced the initiation of a compassionate use program for Namodenoson to treat patients with hepatocellular carcinoma, according to a press release.

The program is being administered by Salomon Stemmer, MD, principal investigator of the phase 2 study of Namodenoson from the Rabin Medical Center, Israel, and has started treating enrolled patients.

“We are grateful to Dr. Stemmer for leading this compassionate use program, making Namodenoson available to patients who have exhausted all other treatment options,” Pnina Fishman, PhD, CEO of Can-Fite, said in the release.

Namodenoson, a small molecule, selective A3 adenosine receptor agonist, is being evaluated as a second line therapy for those with HCC. Data from a recently completed phase 2 study showed that Namodenoson increased overall survival in patients with HCC and Child-Pugh B7.

“Based on the encouraging results of our recent phase 2 trial, in which Namodenoson demonstrated clinical benefits in patients with underlying CPB7 cirrhosis, Can-Fite is committed to providing Namodenoson to fulfill the unmet medical need in this population,” Fishman said.

The FDA agreed with Can-Fite’s proposed phase 3 trial design to support a new drug application submission and approval of Namodenoson in the treatment of HCC.

Reference: www.canfite.com